News

According to the companies, the divested assets will include Xiidra and SAF312, a potential therapy for chronic ocular surface pain. The deal is expected to close later this year.

In his role as president elect, SriniVas Sadda, MD, will continue to serve on the board as well as begin planning for his term as president, which will kick off next May at the conclusion of ARVO’s 2024 Annual Meeting in Seattle, Washington.

As part of its effort, the company is kicking off a new social media campaign in July designed to increase the understanding of dry eye disease.

William B. Trattler, MD, highlights some of the novel therapies for dry eye that have recently been approved by the FDA, along with various treatment approaches that are in development.

The company seeks to replicate European success of the ELIOS procedure in the US market.

Multidisciplinary ophthalmic genetics clinic adds efficiency to process.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg Injection.

An expert discusses how to ensure optimal administration.

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human primate retinas over six months after a single administration, and support plan to advance IG-002 into Phase 1 trials in 2024.

Sparklers and firecrackers are at the top of the list for fireworks-related injuries. The organization is advising the public to leave fireworks to licensed operators.

Experts weigh pros and cons of treatment option for orbital cellulitis in pediatric patients

The funds will be used to further develop the company’s Calibreye System that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.

According to the company, the study will identify hematology biomarkers that could personalize medical evaluations for patients undergoing treatments for macular degeneration.

Surgeons must use caution to avoid pitfalls of complicated procedure

A late breaking poster at the event in San Diego presented by Paolo S. Silva, MD, reveals AI algorithms for diabetic retinopathy progression risk estimation.

According to researchers, the new imaging approach reveals changes in retinal microcirculation may indicate brain diseases that involve reduced blood flow.

Kaushal Solanki, PhD, discusses how ophthalmologists can now use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy.

According to researchers, the study is the first to assess associations between pre-diagnostic circulating metabolites and POAG risk in two large independent datasets.

The company noted the FDA clearance also includes its proprietary Real-Time Quality Feedback to improve the gradeability of retinal images and reduce the need for eye dilation, expanding the choice for primary care clinics to screen people with diabetes.

Keratopigmentation technique offers therapeutic and cosmetic applications.

Cigna’s Coverage Policy includes procedures enabled with OMNI® Surgical System technology as medically necessary and covered.

Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.

Patients with eye disease have an increased risk for developing neurodegenerative disease, and several studies have established a link between neurodegenerative diseases and ophthalmic conditions like glaucoma, diabetic retinopathy, age-related macular degeneration.

Surgeons seek best IOL match for patients after cataract surgery.

In a presentation at the American Society for Microbiology’s annual meeting, the oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

Vitrectomy is a tool that can help surgeons curb complications.